Sally Baron-Hay Clinical Oncology Society of Australia Annual Scientific Meeting 2022

Abstracts this author is presenting:

• Pembrolizumab plus chemotherapy in persistent, recurrent, or metastatic cervical cancer: a KEYNOTE-826 subgroup analysis — Poster session 1
• Neoadjuvant pembrolizumab+chemotherapy vs placebo+chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: event-free survival sensitivity and subgroup analyses from KEYNOTE-522 — Poster session 1